Open AccessRoseomonas gilardii Bacteremia in a Patient With HbSβ0-thalassemia: Clinical Implications and Literature Review
Author(s) -
Charles Schlappi,
Joshua D. Bernstock,
Wilson Ricketts,
Garrett A Nix,
Claudette Poole,
Jeffrey Lebensburger,
Gregory K. Friedman
Publication year - 2019
Publication title -
journal of pediatric hematology/oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.388
H-Index - 78
eISSN - 1536-3678
pISSN - 1077-4114
DOI - 10.1097/mph.0000000000001476
Subject(s) - medicine , bacteremia , meropenem , splenectomy , thalassemia , cephalosporin , pediatrics , intensive care medicine , antibiotics , microbiology and biotechnology , antibiotic resistance , spleen , biology
Roseomonas gilardii is a Gram-negative coccobacillus identified in immunocompromised pediatric patients. A 5-year-old male with a history of HbSβ thalassemia status postsurgical splenectomy presented to the emergency department with fever. Blood cultures grew R. gilardii at 63 hours, but the patient had been discharged home at 48 hours. The patient was readmitted for repeat cultures and initiated on meropenem for 10 days as Roseomonas spp. are often resistant to third generation cephalosporins. R. gilardii is a rare cause of bacteremia in immunocompromised patients. Clinicians should consider Roseomonas in slow growing Gram-negative rod bacteremias, and consider meropenem as empiric coverage.